

Fibrocell Science, Inc.  
Form 8-K  
June 29, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2016

---

FIBROCELL SCIENCE, INC.  
(Exact Name of Registrant as Specified in its Charter)

---

DELAWARE (State or Other Jurisdiction of Incorporation or Organization)	001-31564  (Commission File No.)	87-0458888  (I.R.S. Employer Identification No.)
---	--	---

405 EAGLEVIEW BLVD., EXTON, PA 19341  
(Address of principal executive offices and zip code)

(484) 713-6000  
(Registrant's telephone number, including area code)  
(Former name or former address, if changed from last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 7.01 Regulation FD Disclosure.

On June 29, 2016, Fibrocell Science, Inc. (the "Company" or "Fibrocell") issued a press release announcing the wind-down of its azficel-T operations at its Exton, PA facility and related workforce reductions which are expected to result in significant cost savings as the Company focuses its efforts and resources on its gene therapy portfolio of product candidates. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated June 29, 2016

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Fibrocell Science, Inc.

By: /s/ Keith A. Goldan  
Keith A. Goldan  
SVP and Chief Financial Officer

Date: June 29, 2016